<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="6299"><DrugName>catridecacog</DrugName><DrugNamesKey><Name id="42974294">NovoThirteen</Name><Name id="42987933">Tretten</Name><Name id="42890516">catridecacog</Name></DrugNamesKey><DrugSynonyms><Name><Value>Factor XIII, ZymoGenetics</Value></Name><Name><Value>rFactor XIII, ZymoGenetics</Value></Name><Name><Value>rhFactor XIII, ZymoGenetics</Value></Name><Name><Value>recombinant Factor XIII (congential deficiency), Novo Nordisk</Value></Name><Name><Value>rFactor XIII, Novo Nordisk</Value></Name><Name><Value>rhFactor XIII, Novo Nordisk</Value></Name><Name><Value>recombinant human Factor XIII (congential deficiency, cardiac surgery), Novo Nordisk</Value></Name><Name><Value>rHFXIII, Novo Nordisk</Value></Name><Name><Value>catridecacog</Value><Types><Type>INN</Type></Types></Name><Name><Value>NN-1810</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>rFXIII</Value></Name><Name><Value>NovoThirteen</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>NN-1841</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Tretten</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>NN-8717</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18624">ZymoGenetics Inc</CompanyOriginator><CompaniesPrimary><Company id="18614">Novo Nordisk A/S</Company></CompaniesPrimary><CompaniesSecondary><Company id="18624">ZymoGenetics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="6299" type="Drug"><TargetEntity id="333060" type="siDrug">Catridecacog</TargetEntity></SourceEntity><SourceEntity id="18614" type="Company"><TargetEntity id="4295865996" type="organizationId">Novo Nordisk A/S</TargetEntity></SourceEntity><SourceEntity id="18624" type="Company"><TargetEntity id="4295902009" type="organizationId">Zymogenetics Inc</TargetEntity></SourceEntity><SourceEntity id="189" type="ciIndication"><TargetEntity id="10021972" type="MEDDRA"/><TargetEntity id="D015212" type="MeSH"/><TargetEntity id="-156308446" type="omicsDisease"/><TargetEntity id="394" type="siCondition"/></SourceEntity><SourceEntity id="3045" type="ciIndication"><TargetEntity id="D006348" type="MeSH"/><TargetEntity id="-1544243259" type="omicsDisease"/><TargetEntity id="1044" type="siCondition"/></SourceEntity><SourceEntity id="337" type="ciIndication"><TargetEntity id="K51" type="ICD10"/><TargetEntity id="10009900" type="MEDDRA"/><TargetEntity id="D003093" type="MeSH"/><TargetEntity id="-1993209976" type="omicsDisease"/><TargetEntity id="396" type="siCondition"/></SourceEntity><SourceEntity id="3423" type="ciIndication"><TargetEntity id="10016083" type="MEDDRA"/><TargetEntity id="D005177" type="MeSH"/><TargetEntity id="-952935674" type="omicsDisease"/><TargetEntity id="333" type="siCondition"/></SourceEntity><SourceEntity id="616" type="ciIndication"><TargetEntity id="D89.81" type="ICD10"/><TargetEntity id="10018651" type="MEDDRA"/><TargetEntity id="D006086" type="MeSH"/><TargetEntity id="39812" type="ORPHANET"/><TargetEntity id="-1437372564" type="omicsDisease"/><TargetEntity id="1129" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Factor XIII deficiency - Canada - Dec-2012</FirstLaunched><FirstLaunched>Factor XIII deficiency - EU - Dec-2012</FirstLaunched><FirstLaunched>Factor XIII deficiency - Switzerland - Dec-2012</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="3423">Factor XIII deficiency</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="189">Inflammatory bowel disease</Indication><Indication id="3045">Cardiac surgical procedure</Indication><Indication id="337">Ulcerative colitis</Indication><Indication id="616">Graft versus host disease</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="663">Factor XIII agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="1545">Anticancer</Action><Action id="968">Coagulation stimulator</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="750">Freeze drying</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="85">Protein recombinant</Technology><Technology id="898">Formulation powder</Technology></Technologies><LastModificationDate>2018-08-23T17:48:08.000Z</LastModificationDate><ChangeDateLast>2018-08-25T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18614" linkType="Company"&gt;Novo Nordisk&lt;/ulink&gt;, under license from &lt;ulink linkID="18624" linkType="Company"&gt;ZymoGenetics&lt;/ulink&gt; (a wholly owned subsidiary of &lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt;),  has developed and launched catridecacog (NovoThirteen; Tretten),  a recombinant human Factor XIII (rhFXIII; rFXIII), developed as a powder for solution for iv administration [&lt;ulink linkID="562564" linkType="Reference"&gt;562564&lt;/ulink&gt;]. In the US, the product is indicated for routine prophylaxis of bleeding in patients with congenital FXIII A-subunit deficiency [&lt;ulink linkID="1511282" linkType="Reference"&gt;1511282&lt;/ulink&gt;]. In the EU, the product is indicated for the long-term prevention of bleeding in adults and children aged six and over with congenital FXIII A-subunit deficiency (as NN-1841) [&lt;ulink linkID="1509307" linkType="Reference"&gt;1509307&lt;/ulink&gt;]. In Japan, the drug is indicated for bleeding control in congenital blood coagulation Factor XIII subunit A deficient patients [&lt;ulink linkID="1649878" linkType="Reference"&gt;1649878&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2012, catridecacog was launched in the EU for prophylactic treatment of congenital FXIII A-subunit deficiency [&lt;ulink linkID="1393417" linkType="Reference"&gt;1393417&lt;/ulink&gt;]. In December 2013, the drug was approved in the US for prophylactic treatment of  congenital FXIII A-subunit deficiency, and was presumed to have been launched  in early 2014, as planned [&lt;ulink linkID="1511131" linkType="Reference"&gt;1511131&lt;/ulink&gt;], [&lt;ulink linkID="1515794" linkType="Reference"&gt;1515794&lt;/ulink&gt;].  In August 2015, the drug was launched in Japan for bleeding control in congenital blood coagulation Factor XIII subunit A deficient patients [&lt;ulink linkID="1688589" linkType="Reference"&gt;1688589&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Novo Nordisk was previously developing the formulation for use in  cardiac surgery (as NN-1810). In August 2009, a phase II trial in patients undergoing cardiac surgery was initiated [&lt;ulink linkID="1032006" linkType="Reference"&gt;1032006&lt;/ulink&gt;]. Data from the trial were reported in April 2011; no effect on transfusion avoidance was observed and, based on these data, development for this indication was discontinued [&lt;ulink linkID="1186895" linkType="Reference"&gt;1186895&lt;/ulink&gt;]. Novo Nordisk was also previously developing the  drug (as NN-8717)  for the potential treatment of ulcerative colitis (UC); in October 2012, a phase IIa trial was initiated for this indication [&lt;ulink linkID="1335942" linkType="Reference"&gt;1335942&lt;/ulink&gt;], [&lt;ulink linkID="1336117" linkType="Reference"&gt;1336117&lt;/ulink&gt;]; however, in June 2013, development was discontinued after  results from the study  failed to confirm the  relationship between low FXIII level and disease activity [&lt;ulink linkID="1463240" linkType="Reference"&gt;1463240&lt;/ulink&gt;].   Novo Nordisk was also investigating the drug for cancer; by October 2004, upon receiving rights to the drug from ZymoGenetics, the drug was in preclinical development for cancer by ZymoGenetics [&lt;ulink linkID="618330" linkType="Reference"&gt;618330&lt;/ulink&gt;], [&lt;ulink linkID="476285" linkType="Reference"&gt;476285&lt;/ulink&gt;]; by December 2009, the Novo Nordisk terminated development of the drug within the cancer indication [&lt;ulink linkID="1076180" linkType="Reference"&gt;1076180&lt;/ulink&gt;].  ZymoGenetics was previously developing the product for  inflammatory bowel disease (IBD) and was investigating it for potential use in graft versus host disease (GvHD). By October 2004, when the product was acquired by Novo Nordisk, ZymoGenetics  had completed several phase I trials  [&lt;ulink linkID="562330" linkType="Reference"&gt;562330&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Novo Nordisk has  also developed and launched &lt;ulink linkID="3089" linkType="Drug"&gt;NovoSeven&lt;/ulink&gt; (rFVIIa).&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In February 2014, Novo Nordisk stated that ex-US patent coverage had expired; in the US it is protected until 2021 and  might also benefit from a patent term extension of up to 2 years [&lt;ulink linkID="1529608" linkType="Reference"&gt;1529608&lt;/ulink&gt;]; in February 2017, the company noted that data protection in the US runs until 2025 [&lt;ulink linkID="1898693" linkType="Reference"&gt;1898693&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In June 2003, the FDA granted Orphan Drug designation for the treatment of FXIII deficiency  [&lt;ulink linkID="492346" linkType="reference"&gt;492346&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2011, a BLA was submitted to the FDA for the treatment of congenital FXIII deficiency [&lt;ulink linkID="1170509" linkType="Reference"&gt;1170509&lt;/ulink&gt;]. By January 2012, a complete response letter had been issued; the FDA required additional information prior to approval and, at the time, Novo Nordisk was reviewing the content of the response and planned to work closely with FDA to provide the additional data [&lt;ulink linkID="1259548" linkType="Reference"&gt;1259548&lt;/ulink&gt;]. By January 2013, the BLA had been resubmitted [&lt;ulink linkID="1364778" linkType="Reference"&gt;1364778&lt;/ulink&gt;]. In June 2013, the company received a second complete response letter [&lt;ulink linkID="1509507" linkType="Reference"&gt;1509507&lt;/ulink&gt;]; in October 2013, the company resubmitted the regulatory application to the FDA [&lt;ulink linkID="1496385" linkType="Reference"&gt;1496385&lt;/ulink&gt;]. In December 2013, the drug was approved in the US for the routine prophylaxis of bleeding in people with congenital FXIII A-subunit deficiency; at that time, launch was expected in early 2014; launch was preseumed to have occured as planned [&lt;ulink linkID="1511131" linkType="Reference"&gt;1511131&lt;/ulink&gt;], [&lt;ulink linkID="1515794" linkType="Reference"&gt;1515794&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;By October 2012, the drug was approved in Switzerland [&lt;ulink linkID="1335942" linkType="Reference"&gt;1335942&lt;/ulink&gt;]; launch was presumed to have occurred shortly after.&lt;/para&gt;&lt;para&gt;By June 2011, an MAA had been submitted under the centralized procedure [&lt;ulink linkID="1200721" linkType="Reference"&gt;1200721&lt;/ulink&gt;]. In May 2012, the EMA's CHMP issued a positive opinion, recommending approval of catridecacog for long-term prophylactic treatment of bleeding in patients &amp;gt;/= 6 years with congenital FXIII A-subunit  deficiency [&lt;ulink linkID="1294656" linkType="Reference"&gt;1294656&lt;/ulink&gt;]. In September 2012, the drug was approved in the EU for the long-term prevention of bleeding in adults and children aged six and over with congenital factor XIII A-subunit deficiency [&lt;ulink linkID="1509307" linkType="Reference"&gt;1509307&lt;/ulink&gt;]. By December 2012, catridecacog was launched in the EU [&lt;ulink linkID="1393417" linkType="Reference"&gt;1393417&lt;/ulink&gt;]. In July 2013, the drug was launched in Norway [&lt;ulink linkID="1458761" linkType="Reference"&gt;1458761&lt;/ulink&gt;]. In January 2014, the  CHMP of the EMEA recommended an extension of indication for long term prophylactic treatment of bleeding in adult and pediatric patients with congenital factor XIII A-subunit deficiency [&lt;ulink linkID="1518359" linkType="Reference"&gt;1518359&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2003, the drug received Orphan Drug status in the EU [&lt;ulink linkID="1509307" linkType="Reference"&gt;1509307&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In May 2014, catridecacog was granted Orphan designation in Japan for bleeding control in congenital blood coagulation Factor XIII subunit A deficient patients [&lt;ulink linkID="1585523" linkType="Reference"&gt;1585523&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, the Pharmaceutical Affairs and Food Sanitation Council's Second Committee was to discuss the approval recommendation for the drug in Japan on March 05, 2015 [&lt;ulink linkID="1640201" linkType="Reference"&gt;1640201&lt;/ulink&gt;]. In March 2015, the committee recommended approval of the drug [&lt;ulink linkID="1644044" linkType="Reference"&gt;1644044&lt;/ulink&gt;]. Later that month, the drug was approved for bleeding control in congenital blood coagulation Factor XIII subunit A deficient patients [&lt;ulink linkID="1649878" linkType="Reference"&gt;1649878&lt;/ulink&gt;]. In August 2015, the drug was launched in Japan [&lt;ulink linkID="1688589" linkType="Reference"&gt;1688589&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In July 2012, catridecacog was approved in Canada as a once-monthly routine prophylaxis treatment for bleeding in patients with congenital factor XIII A-subunit deficiency.  At that time, launch was expected in 2H12 under the brand name Tretten. The product had been granted Priority Review status  [&lt;ulink linkID="1314658" linkType="Reference"&gt;1314658&lt;/ulink&gt;], [&lt;ulink linkID="1314260" linkType="Reference"&gt;1314260&lt;/ulink&gt;]. By December 2012, the drug had been launched in Canada [&lt;ulink linkID="1364778" linkType="Reference"&gt;1364778&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;In December 2012, the product was filed for approval in Israel. In December 2013, catridecacog was approved for    the long-term prophylactic treatment of bleeding in patients age 1 year and above with congenital Factor XIII A-subunit deficiency [&lt;ulink linkID="2066325" linkType="Reference"&gt;2066325&lt;/ulink&gt;]; however, by August 2018, the product was not being marketed in Israel   [&lt;ulink linkID="2066327" linkType="Reference"&gt;2066327&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In November 2011, the drug received Orphan status in Australia [&lt;ulink linkID="1268600" linkType="Reference"&gt;1268600&lt;/ulink&gt;]. In November 2013, the drug (as NovoThirteen) was approved in Australia for routine prophylaxis of bleeding in patients with congenital, Factor XIII A-subunit deficiency [&lt;ulink linkID="1511131" linkType="Reference"&gt;1511131&lt;/ulink&gt;], [&lt;ulink linkID="1573085" linkType="Reference"&gt;1573085&lt;/ulink&gt;]. By August 2018, the product had been launched [&lt;ulink linkID="2066318" linkType="Reference"&gt;2066318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, catridecacog was approved as NovoThirteen in Taiwan, presumably for factor XIII deficiency [&lt;ulink linkID="1945001" linkType="Reference"&gt;1945001&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In May 2013, a prospective multicenter, observational clinical study (&lt;ulink linkID="134371" linkType="Protocol"&gt;NCT01862367&lt;/ulink&gt;; Mentor 6; NN1841-3868; U1111-1131-1558) was started in Denmark, to access the efficacy of catridecacog in the treatment of patients with congenital FXIII deficiency (expected n = 40). At that time, the study was expected to complete by June 2018 [&lt;ulink linkID="1440164" linkType="Reference"&gt;1440164&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Congenital FXIII deficiency&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In December 2013, clinical data from post-hoc analysis of three clinical studies (F13CD-1725, F13CD-3760 and F13CD-3720) were presented at the 55th ASH Meeting in New Orleans, LA. There were no statistically significant differences in the pharmacokinetic parameters between the groups. The mean pharmacokinetic profiles were comparable across the three studies. The Cmax, Ctrough and AUC (factor XIII exposure) values remained constant over time [&lt;ulink linkID="1503803" linkType="Reference"&gt;1503803&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2013, data from a phase III trial had demonstrated that the drug was effective in the prevention of bleeding following once-monthly dosing for 12 months. Also, the drug was generally found to be safe with only transient, non-neutralising antibody formation in few patients [&lt;ulink linkID="1496385" linkType="Reference"&gt;1496385&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2011, a non-randomized, open-label, single-group, phase III extension study (&lt;ulink linkID="72782" linkType="Protocol"&gt;NCT01253811&lt;/ulink&gt;; Mentor 5; F13CD-3835; U1111-1117-1063; 2010-020192-23) to NCT01230021 was initiated in the US, UK and Israel to investigate the long-term safety of monthly replacement therapy of catridecacog in children (n = 6) aged 1 to 6 years old with congenital FXIII deficiency. The primary endpoint was the number of treatment emergent (serious and non-serious) adverse events.  At that time, the trial was expected to complete in December 2014. In October 2013, the trial was ongoing and was expected to complete in August 2014; the trial could possibly be extended up to a maximum of 3 years dependent on when the drug would be commercially available in the respective country for use in children of 1 to 6 years of age [&lt;ulink linkID="1509576" linkType="Reference"&gt;1509576&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2010, a phase III, non-randomized, open-label, single-group study (&lt;ulink linkID="71851" linkType="Protocol"&gt;NCT01230021&lt;/ulink&gt;; Mentor 4; F13CD-3760; U1111-1116-2533; 2009-016869-28) began to assess the safety and pharmacokinetics of catridecacog in the US, UK and Israel in children (n = 6) aged 1 to 6 years old with congenital FXIII deficiency. The primary endpoint was the area under the concentration versus time curve  from day 0 to 30. By January 2012, the trial was completed [&lt;ulink linkID="1509569" linkType="Reference"&gt;1509569&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2009, a non-randomized, open-label, phase III extension study (&lt;ulink linkID="60405" linkType="Protocol"&gt;NCT00978380&lt;/ulink&gt;; Mentor 2; F13CD-3720; 2008-007883-41; U1111-1111-9289; JapicCTI-121958) to &lt;ulink linkID="31633" linkType="Protocol"&gt;NCT00713648&lt;/ulink&gt; was initiated in the US, Canada, Europe and Israel to investigate the safety of monthly replacement therapy of catridecacog in patients (expected n = 60) with congenital FXIII deficiency. By September 2012, recruitment had also been initiated in Japan; at that time, trial completion was expected in May 2013. By October 2013, the trial was ongoing and was expected to complete in December 2015  [&lt;ulink linkID="1340555" linkType="Reference"&gt;1340555&lt;/ulink&gt;]. In July 2017, clinical data were presented at the XXVI ISTH Congress in Berlin, Germany. A total of 12 minor procedures were performed in nine patients. Of these 12 procedures, 8 were performed within 7 days of the patient's last scheduled rFXIII-A2 dose and 4 were performed 10 to 21 days following the last dose. There was no additional FXIII substitution required for any procedure. In four procedures (tooth extraction (n = 3) and colonoscopy (n = 1)), concomitant antifibrinolytics were used. There were no adverse events reported as possibly/probably related to rFXIII-A2 treatment [&lt;ulink linkID="1947738" linkType="Reference"&gt;1947738&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2008, a non-randomized, open label, historical-control, single-group, safety and efficacy, phase III  trial (&lt;ulink linkID="31633" linkType="Protocol"&gt;NCT00713648&lt;/ulink&gt;; F13CD-1725; Mentor) began in  the US, Canada, Europe and Israel. Patients with congenital FXIII A-subunit deficiency (expected n = 40) were to receive rFXIII (35 IU/kg body weight iv once every 4 weeks) with the primary outcome measure of rate of bleeding episodes (number per subject year) requiring treatment with a FXIII-containing product during the rFXIII treatment period [&lt;ulink linkID="944117" linkType="Reference"&gt;944117&lt;/ulink&gt;]. In April 2009, enrollment of 41 patients was complete [&lt;ulink linkID="1004588" linkType="Reference"&gt;1004588&lt;/ulink&gt;]. In August 2010, results from the study showed the drug was safe and significantly reduced the annual number of bleeding episodes that required treatment, compared with a historical control group, who did not receive prophylactic infusions [&lt;ulink linkID="1121554" linkType="Reference"&gt;1121554&lt;/ulink&gt;]. In December 2010, results from the trial were presented at the American Society of Hematology (ASH). A total of five bleeding episodes, which were associated with trauma and required additional FXIII treatment, were observed in four patients receiving rhFVIII. No intracranial hemorrhage or spontaneous bleeds requiring treatment were observed. The annual rate of bleeds requiring treatment (estimated as 0.048 bleeds/patient/year) in rhFVIII-treated patients was less than the historic bleeding rate of 2.91. The crude mean rate of bleeding for rhFVIII-treated patients was 0.138 bleeds/patient/year. Low FXIII activity levels in rhFVIII-treated patients were not associated with bleeds requiring treatment. The average FXIII activity at 1 h post-dose was 77.0%, and the mean incremental increase in activity from pre-dose to 1 h post-dose was 1.68% /IU/ kg. Transient, non-neutralizing, low-titer anti-rFXIII antibodies were observed in four rhFVIII-treated patients; no anaphylactic or allergic reactions, bleeding episodes or changes in FXIII pharmacokinetics were reported in these patients. In addition, non-neutralizing antibodies decreased to below the limit of detection in all patients. No thromboembolic events or fatal adverse events were reported [&lt;ulink linkID="1150780" linkType="Reference"&gt;1150780&lt;/ulink&gt;], [&lt;ulink linkID="1170509" linkType="Reference"&gt;1170509&lt;/ulink&gt;]. In 2012, similar data from the trial were published [&lt;ulink linkID="1336406" linkType="Reference"&gt;1336406&lt;/ulink&gt;].  In December 2012, similar data were presented at the 54th ASH Meeting in Atlanta, GA [&lt;ulink linkID="1346685" linkType="Reference"&gt;1346685&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;By March 2005, phase II studies were planned [&lt;ulink linkID="591055" linkType="Reference"&gt;591055&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In December 2003, phase I clinical data were presented at the 45th ASH meeting in San Diego, CA. Five cohorts of two FXIII deficient patients received doses of 2, 6, 20, 50 and 75 U/kg of rhFXIII respectively. Nine subjects with previously diagnosed congenital FXIII deficiency were enrolled. Preliminary data indicated that all subjects with baseline abnormal urea clot solubility showed normalization within 30 min. All FXIIIA subunit deficient patients with undetectable FXIII at baseline had detectable A2B2 complexes noted in plasma at 30 min, even at the lowest dose studied. Free B subunit levels also dropped during the first 30 to 60 min following returning slowly to baseline. One subject was FXIII-B subunit deficient and the survival of the recombinant A2 homodimer was studied in this patient at the 50 U/kg dose. Factor XIII activity rose to 105% by 30 min but decreased to less than 10% at 48 h. B subunit levels were undetectable at all timepoints. At doses that raised the FXIII level by at least 50%, the maximum amplitude increased significantly indicating a stronger clot was formed and the percent lysis at 60 min normalized suggesting the clot was more resistant to fibrinolysis. No serious adverse events were noted [&lt;ulink linkID="515868" linkType="reference"&gt;515868&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2003, single-dose escalation phase I trials were ongoing in the US in patients with congenital FXIII deficiency and in the UK in healthy volunteers [&lt;ulink linkID="477997" linkType="reference"&gt;477997&lt;/ulink&gt;]. By May 2003, enrollment in the UK trial had been completed [&lt;ulink linkID="488801" linkType="reference"&gt;488801&lt;/ulink&gt;]. In June 2003, ZymoGenetics expected to complete the study and report the results by the end of 2003. By that time, initial results from the initial single-dose study illustrated that treatment with rhFXIII appeared to be well tolerated, with no serious adverse events noted for any of the 50 subjects enrolled in the trial [&lt;ulink linkID="492346" linkType="reference"&gt;492346&lt;/ulink&gt;]. In July 2003, further data from the phase I dose-escalation trial were presented at the 19th ISTH conference in Birmingham, UK. Cohorts of 10 subjects were randomized to study drug versus placebo in an 8:2 ratio. Dose levels were 2, 5, 10, 25, and 50 unit/kg. The subjects were given a single intravenous injection, and then followed for 28 days. No serious adverse events were observed in any of the subjects, with headache being the most common side effect observed. Administration of rhFXIII did not elicit an antibody response in any subject. The half-life of circulating rhFXIII activity following administration was 9  to 11 days [&lt;ulink linkID="497111" linkType="reference"&gt;497111&lt;/ulink&gt;], [&lt;ulink linkID="499574" linkType="reference"&gt;499574&lt;/ulink&gt;]. In December 2003, these data were also presented at the 45th ASH meeting in San Diego, CA [&lt;ulink linkID="515869" linkType="reference"&gt;515869&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2002, ZymoGenetics filed an IND for the initiation of a phase I study of rhFXIII in patients with congenital FXIII deficiency [&lt;ulink linkID="464159" linkType="reference"&gt;464159&lt;/ulink&gt;], [&lt;ulink linkID="425433" linkType="reference"&gt;425433&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ulcerative colitis&lt;/subtitle&gt;In October 2012, a randomized, double-blind, placebo-controlled, phase IIa trial (&lt;ulink linkID="94769" linkType="Protocol"&gt;NCT01706159&lt;/ulink&gt;; NN8717-3946; 2011-001568-22; U1111-1120-3824) was initiated in Europe in patients (expected n =  90) with mild to moderate active UC. At that time, trial completion was expected in  January 2014 [&lt;ulink linkID="1335942" linkType="Reference"&gt;1335942&lt;/ulink&gt;], [&lt;ulink linkID="1336117" linkType="Reference"&gt;1336117&lt;/ulink&gt;]. In June 2013, the study was discontinued after the relationship between low FXIII level and disease activity could not be confirmed [&lt;ulink linkID="1463240" linkType="Reference"&gt;1463240&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cardiac surgery&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2009, the company planned to start a phase II trial in patients undergoing cardiac surgery in 2009 [&lt;ulink linkID="983568" linkType="Reference"&gt;983568&lt;/ulink&gt;]. By August 2009, a phase IIa trial in cardiac surgery patients had begun. The trial was to assess the safety and efficacy of the product in 400 heart surgery patients. At that time, data were expected in early 2011 [&lt;ulink linkID="1032006" linkType="Reference"&gt;1032006&lt;/ulink&gt;]. Data were reported in April 2011. No effect on transfusion avoidance was observed. Based on these data, development for this indication was discontinued [&lt;ulink linkID="1186895" linkType="Reference"&gt;1186895&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In October 2005, Novo Nordisk began a phase I trial in  patients undergoing cardiac surgery. The study was to evaluate the safety of a range of rFXIII doses in patients being treated at major hospitals in North America and Europe [&lt;ulink linkID="629225" linkType="Reference"&gt;629225&lt;/ulink&gt;]. The  43-patient, dose-escalation study was completed by April 2008. Results   confirmed the ability of rhFXIII  normalized  FXIII levels in the blood [&lt;ulink linkID="900955" linkType="Reference"&gt;900955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2003, phase I trials in CPB and GvHD were expected to begin in 2003 [&lt;ulink linkID="476285" linkType="reference"&gt;476285&lt;/ulink&gt;]. In December 2003, the FDA requested more data for the proposed CPB study, which set back the planned start date to 2004 [&lt;ulink linkID="515890" linkType="reference"&gt;515890&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Inflammatory bowel disease&lt;/subtitle&gt;By 1999, ZymoGenetics had discontinued development of rhFXIII for the treatment of IBD. The product, which was being investigated in collaboration with the &lt;ulink linkID="20701" linkType="Company"&gt;University of Washington&lt;/ulink&gt;, had reached phase I trials [&lt;ulink linkID="348949" linkType="reference"&gt;348949&lt;/ulink&gt;]; by October 2001, the company had re-initiated its evaluation of rhFXIII for IBD as well as for additional indications [&lt;ulink linkID="425433" linkType="reference"&gt;425433&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In February 2016, clinical data from a study in 72 severe FXIII-A deficiency patients with F13A1 mutations were presented at the Ninth EAHAD Annual Congress in Malmo, Sweden. Patients received rFXIII-A2. None of the patients developed FXIII neutralizing antibodies [&lt;ulink linkID="1731986" linkType="Reference"&gt;1731986&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By October 2004, the drug was in preclinical development for cancer [&lt;ulink linkID="618330" linkType="Reference"&gt;618330&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 1996, it had been shown that in a rat model of TNBS-induced intestinal inflammation, rhFXIII was efficacious for the treatment of both the acute and chronic phases of  the experimentally induced colitis. It also reduced the time to recovery for both the developing and established lesions and was effective for at least 18 days after treatment was terminated [&lt;ulink linkID="210468" linkType="reference"&gt;210468&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In December 2010, the EMA approved a modified pediatric investigation plan [&lt;ulink linkID="1268597" linkType="Reference"&gt;1268597&lt;/ulink&gt;]. In July 2012, the pediatric committee adopted a positive opinion on a modified pediatric investigation plan [&lt;ulink linkID="1308399" linkType="Reference"&gt;1308399&lt;/ulink&gt;]. In December 2016, the PDCO adopted a positive opinion on full compliance check for catridecacog for the treatment of congenital FXIII A-subunit deficiency [&lt;ulink linkID="1893809" linkType="Reference"&gt;1893809&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2018-08-23T00:00:00.000Z</StatusDate><Source id="2066318" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2013-07-01T00:00:00.000Z</StatusDate><Source id="1458761" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1393417" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2015-08-27T00:00:00.000Z</StatusDate><Source id="1688589" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2014-06-30T00:00:00.000Z</StatusDate><Source id="1515794" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1335942" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1393417" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate><Source id="2066327" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2017-06-27T00:00:00.000Z</StatusDate><Source id="1945001" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1076180" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3045">Cardiac surgical procedure</Indication><StatusDate>2011-04-28T00:00:00.000Z</StatusDate><Source id="1186895" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18624">ZymoGenetics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2001-01-01T00:00:00.000Z</StatusDate><Source id="425433" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18624">ZymoGenetics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2001-01-01T00:00:00.000Z</StatusDate><Source id="476285" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18614">Novo Nordisk A/S</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate>2013-06-30T00:00:00.000Z</StatusDate><Source id="1463240" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18624">ZymoGenetics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="616">Graft versus host disease</Indication><StatusDate>2001-01-01T00:00:00.000Z</StatusDate><Source id="476285" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18624">ZymoGenetics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-10-05T00:00:00.000Z</StatusDate><Source id="476285" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18624">ZymoGenetics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3045">Cardiac surgical procedure</Indication><StatusDate>2004-10-05T00:00:00.000Z</StatusDate><Source id="476285" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18624">ZymoGenetics Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2004-10-05T00:00:00.000Z</StatusDate><Source id="477997" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2008-08-21T00:00:00.000Z</StatusDate><Source id="944117" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2011-06-14T00:00:00.000Z</StatusDate><Source id="1200721" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2012-07-19T00:00:00.000Z</StatusDate><Source id="1314658" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate>2012-10-18T00:00:00.000Z</StatusDate><Source id="1336117" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18624">ZymoGenetics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-10-05T00:00:00.000Z</StatusDate><Source id="618330" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-10-05T00:00:00.000Z</StatusDate><Source id="476285" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2012-09-03T00:00:00.000Z</StatusDate><Source id="1509307" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2011-02-23T00:00:00.000Z</StatusDate><Source id="1170509" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2012-09-11T00:00:00.000Z</StatusDate><Source id="1340555" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2015-02-20T00:00:00.000Z</StatusDate><Source id="1640201" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2015-03-26T00:00:00.000Z</StatusDate><Source id="1688589" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2013-12-22T00:00:00.000Z</StatusDate><Source id="1515794" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2013-11-04T00:00:00.000Z</StatusDate><Source id="1573085" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2012-10-31T00:00:00.000Z</StatusDate><Source id="1335942" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2008-08-21T00:00:00.000Z</StatusDate><Source id="944117" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="IL">Israel</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="2066325" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18624">ZymoGenetics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18624">ZymoGenetics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>1996-07-01T00:00:00.000Z</StatusDate><Source id="210468" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18624">ZymoGenetics Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2003-02-04T00:00:00.000Z</StatusDate><Source id="477997" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18624">ZymoGenetics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18624">ZymoGenetics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18624">ZymoGenetics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3045">Cardiac surgical procedure</Indication><StatusDate>2003-01-09T00:00:00.000Z</StatusDate><Source id="476285" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18624">ZymoGenetics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="189">Inflammatory bowel disease</Indication><StatusDate>2001-10-12T00:00:00.000Z</StatusDate><Source id="425433" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2005-10-18T00:00:00.000Z</StatusDate><Source id="629225" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2005-10-18T00:00:00.000Z</StatusDate><Source id="629225" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3045">Cardiac surgical procedure</Indication><StatusDate>2009-08-06T00:00:00.000Z</StatusDate><Source id="1032006" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18614">Novo Nordisk A/S</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3423">Factor XIII deficiency</Indication><StatusDate>2008-08-21T00:00:00.000Z</StatusDate><Source id="944117" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18614">Novo Nordisk A/S</OwnerCompany><Country id="JP">Japan</Country><Indication id="3423">Factor XIII deficiency</Indication><AwardedIndication>Bleeding control in patients with congenital factor XIII subunit A deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2014-05-13T00:00:00.000Z</MileStoneDate><Source id="1585523" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18614">Novo Nordisk A/S</OwnerCompany><Country id="EU">EU</Country><Indication id="3423">Factor XIII deficiency</Indication><AwardedIndication>Treatment of hereditary factor-XIII deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate>2012-11-29T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="19614">Ischemia Research and Education Foundation</OwnerCompany><Country id="AU">Australia</Country><Indication id="3423">Factor XIII deficiency</Indication><AwardedIndication>Routine prophylaxis for bleeding in patients with congenital Factor XIII A subunit deficiency.</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2011-11-22T00:00:00.000Z</MileStoneDate><Source id="1268600" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18614">Novo Nordisk A/S</OwnerCompany><Country id="EU">EU</Country><Indication id="3423">Factor XIII deficiency</Indication><AwardedIndication>Treatment of hereditary factor-XIII deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2004-12-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18614">Novo Nordisk A/S</OwnerCompany><Country id="EU">EU</Country><Indication id="3423">Factor XIII deficiency</Indication><AwardedIndication>Treatment of hereditary factor-XIII deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2003-12-12T00:00:00.000Z</MileStoneDate><Source id="1509307" type="OTHER"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18614">Novo Nordisk A/S</OwnerCompany><Country id="US">US</Country><Indication id="3423">Factor XIII deficiency</Indication><AwardedIndication>Prophylaxis of bleeding associated with congential factor XIII deficiency</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2003-11-06T00:00:00.000Z</MileStoneDate><Source id="492346" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18614">Novo Nordisk A/S</OwnerCompany><Country id="EU">EU</Country><Indication id="3423">Factor XIII deficiency</Indication><AwardedIndication>Treatment of hereditary factor-XIII deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2003-11-06T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18614">Novo Nordisk A/S</OwnerCompany><Country id="US">US</Country><Indication id="3423">Factor XIII deficiency</Indication><AwardedIndication>Treatment of congenital FXIII deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2003-05-21T00:00:00.000Z</MileStoneDate><Source id="492346" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18624">ZymoGenetics Inc</OwnerCompany><Country id="US">US</Country><Indication id="3423">Factor XIII deficiency</Indication><AwardedIndication>Treatment of congenital factor XIII deficiency.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1993-04-22T00:00:00.000Z</MileStoneDate><Source id="492346" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00724"><Name>Factor XIII</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>4 references added [&lt;ulink url="utility.reference?i_reference_id=2066327" linkType="reference" linkID="2066327"&gt;2066327&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2066317" linkType="reference" linkID="2066317"&gt;2066317&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2066325" linkType="reference" linkID="2066325"&gt;2066325&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2066318" linkType="reference" linkID="2066318"&gt;2066318&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="18614">Novo Nordisk A/S</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19076">PPL Therapeutics plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20701">University of Washington</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="107399" title="Novo Nordisk to develop ZymoGenetics' Factor XIII portfolio worldwide"/><Deal id="122644" title="The University of Washington to collaborate with ZymoGenetics on Factor XIII"/><Deal id="122645" title="PPL Therapeutics to use rhFXIII from ZymoGenetics as a component to its Fibrin glue"/></Deals><PatentFamilies><PatentFamily id="1100000" number="WO-02067980" title="Method For Treating Von Willebrand'S Disease"/><PatentFamily id="1290705" number="WO-2006021584" title="Purification of factor XIII polypeptides from biological materials"/><PatentFamily id="1612187" number="WO-09312813" title="Methods and compositions for reducing blood loss."/><PatentFamily id="1805715" number="WO-02067981" title="Blood Coagulation Factor Xiii For Treating Platelet Disorders"/><PatentFamily id="2027766" number="WO-00238167" title="Method for treating hemophilia B"/><PatentFamily id="2101807" number="WO-00236155" title="Use Of Blood Coagulation Factor Xiii For Treating Haemophilia A"/><PatentFamily id="2134322" number="WO-2005115442" title="Use of coagulation factor XIII for treatment of post surgical bleedings"/><PatentFamily id="2250956" number="WO-2004017921" title="Method for treating inflammatory bowel disease"/><PatentFamily id="2310321" number="EP-00268772" title="Expression of biologically active factor XIII"/><PatentFamily id="3510996" number="WO-2017009136" title="Factor XIII for the treatment of interstitial cystitis"/><PatentFamily id="74731" number="WO-2010046468" title="Method of quality control testing a factor XIII containing sample"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>7</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Baxter International Inc" id="14437"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"/><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CSL Ltd" id="15563"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novo Nordisk A/S" id="18614"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Washington" id="20701"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></drugRecordOutput>